V. Limmroth
AuthID: R-00J-5FW
1
TITLE: Alemtuzumab efficacy and safety were maintained over 8 years in relapsing-remitting multiple sclerosis patients with highly active disease from CARE-MS I: TOPAZ study follow-up Full Text
AUTHORS: Limmroth, V; Achiron, A; Bass, AD; Bertolotto, A; Brandes, D; Chinea, A; Garcia, JR; Naismith, RT; Schippling, S; Sharrack, B; Sousa, L; Tintore, M; Traboulsee, A; Uitdehaag, BMJ; Ziemssen, T; Choudhry, Z; Daizadeh, N; Pelletier, D;
PUBLISHED: 2019, SOURCE: 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS in MULTIPLE SCLEROSIS JOURNAL, VOLUME: 25
AUTHORS: Limmroth, V; Achiron, A; Bass, AD; Bertolotto, A; Brandes, D; Chinea, A; Garcia, JR; Naismith, RT; Schippling, S; Sharrack, B; Sousa, L; Tintore, M; Traboulsee, A; Uitdehaag, BMJ; Ziemssen, T; Choudhry, Z; Daizadeh, N; Pelletier, D;
PUBLISHED: 2019, SOURCE: 35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS) / 24th Annual Conference of Rehabilitation in MS in MULTIPLE SCLEROSIS JOURNAL, VOLUME: 25
INDEXED IN: 
WOS
WOS